Investigational drug · Phase 2
StromaForte
Also called: Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product, MSCs, Human Allogeneic Bone-Marrow -Derived Mesenchymal Stromal Cells Product
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiovascular Diseases, Frailty, Musculoskeletal Injury.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
5
Any phase or sponsor naming "StromaForte"
First trial start
2023
Oct 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "StromaForte", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cardiovascular Diseases
- Frailty
- Musculoskeletal Injury
- MSA - Multiple System Atrophy
- MSA
- Aging Frailty
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "StromaForte" as an intervention, largest first.
- A Study to Evaluate Mesenchymal Stem Cell Product StromaForte's Effect on Cardiovascular EventsRecruiting
Cellcolabs Clinical LTD.Industry
NCT06087848 · 100 participants (planned) · Start Oct 7, 2023 · Primary completion Oct 6, 2029
Drug: Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte) · For: Cardiovascular Diseases
Sites: Nassau, The Bahamas
Cellcolabs Clinical LTD.Industry
NCT06074783 · 30 participants (planned) · Start Oct 20, 2023 · Primary completion Oct 19, 2027
Drug: Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte) · For: Musculoskeletal Injury
Sites: Nassau, The Bahamas
Cellcolabs Clinical SPV LimitedIndustry
NCT06063590 · 12 participants · Start Jan 22, 2024 · Primary completion Aug 28, 2025
Drug: StromaForte · For: Aging Frailty
Sites: Abu Dhabi, United Arab Emirates
- A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging FrailtyNot yet recruiting
Cellcolabs Clinical LTD.Industry
NCT06070532 · 12 participants (planned) · Start Jan 1, 2025 · Primary completion Jan 1, 2026
Drug: Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte) · For: Frailty
Sites: Nassau, The Bahamas
Cellcolabs Clinical SPV LimitedIndustry
NCT06084988 · 12 participants · Start Nov 7, 2023 · Primary completion Oct 29, 2024
Drug: Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte) · For: Osteo Arthritis Knee
Sites: Abu Dhabi, United Arab Emirates
Newest research
PubMed records naming it or its code names, newest first.
- Targeting the lactate/P300/H3K18la epigenetic pathway with a mechanoadaptive biomimetic hydrogel to suppress traumatic tendon heterotopic ossification.
Feng H, Ang K, Deng Z, et al. · Bioact Mater 2027
- Dynamic tensile conditioning of mesenchymal stem cell-laden auxetic scaffolds for enhanced YAP-dependent miR-30 enrichment in extracellular vesicles for pulmonary fibrosis therapy.
Chen JX, Ho CC, Lin YH, et al. · Biomaterials 2027
- The miR-6538 in extracellular vesicles derived from lycorine-pretreated mesenchymal stem cells enhances therapeutic efficacy in rheumatoid arthritis.
Zheng W, Xu X, Yang C, et al. · Biomaterials 2027
- PTHrP suppresses BMP2-induced osteochondral differentiation and preserves cartilage phenotype in mesenchymal stem cells via inactivating PI3K-AKT signaling.
Gao S, Zhao P, Du T, et al. · Genes Dis 2027
- Bone marrow ECM-based vascular niche modeling for the evaluation of HSC/leukemic cell interaction with niche cells.
Huang Y, Peng P, Huang T, et al. · Biomater Adv 2027
- A multifunctional MOF-mineralized conductive hydrogel coating on zinc implants orchestrates neuro-osteogenic coupling for enhanced bone defect repair.
Wei Y, Mo D, Pan M, et al. · Bioact Mater 2027
Also in development for Cardiovascular Diseases
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- LepodisiranLY3819469Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- MosliciguatPhase 32 trials
Pulmovant, Inc. · Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases
- RalinepagAPD811Phase 32 trials
United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- SPC 2002Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension, Essential, Cardiovascular Diseases, Cardiology
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.